Adverum Q2 2023 Earnings Report
Key Takeaways
Adverum Biotechnologies announced the completion of enrollment in its Phase 2 LUNA trial evaluating Ixo-vec for wet AMD treatment and reported financial results for the second quarter ended June 30, 2023. The company's cash runway is projected into 2025.
Completed enrollment in Phase 2 LUNA trial evaluating Ixo-vec for wet AMD.
Combined OPTIC and LUNA trials will follow approximately 90 wet AMD subjects dosed with Ixo-vec out to five years.
Anticipate aflibercept protein levels for percentage of cohort with a minimum of 14 weeks of follow-up as of data cutoff in late Q3 2023.
Cash runway projected into 2025.
Adverum
Adverum
Forward Guidance
Adverum anticipates aflibercept protein levels for the percentage of cohort with a minimum of 14 weeks of follow-up as of data cutoff in late Q3 2023 and anticipates LUNA preliminary efficacy and safety data for percentage of cohort in Q4 2023.